When Hypopituitarism presents with Central Hypothyroidism (CH), the underlying mechanism and the treatment target differ meaningfully from primary thyroid disease. This protocol addresses that specific clinical situation.
Central Hypothyroidism is caused by insufficient TSH stimulation of a normal thyroid gland, resulting from inadequate secretion or action of TSH-releasing hormone and/or TSH. This pituitary-driven origin distinguishes the condition and shapes how treatment is selected and monitored.
First-line management centres on Levothyroxine (L-T4) therapy dosed to bring thyroid hormone levels into a defined target range.
The primary goal is achievement of serum fT4 levels in the mid to upper half of the reference range — a key distinction from TSH-guided targets used in primary hypothyroidism.
DOI: 10.1210/jc.2016-2118
CH is caused by insufficient TSH stimulation of a normal thyroid gland due to the inadequate secretion or action of TSH-releasing hormone and/or TSH.
We recommend L-T4 in doses sufficient to achieve serum fT4 levels in the mid to upper half of the reference range.
Appropriate L-T4 doses in CH average 1.6 µg/kg/d, with dose adjustments based on clinical context, age, and fT4 levels.
View source ↗